Santen’s Eye Treatment First to Get European Approval

Santen Pharmaceutical has received marketing approval from the European Commission for its ophthalmic treatment Ikervis. The drug is the first in Europe to treat severe keratitis (inflammation of the cornea) in adults with dry eye disease.

The approval is supported by a phase III clinical programme investigating the efficacy and safety of cyclosporine, the active ingredient in Ikervis.

Masamichi Sato, head of Santen Europe and president of Santen Holdings EU, commented: "We are delighted with the approval that offers dry eye disease patients with severe keratitis the first prescription treatment in Europe. Our commitment is to continue to deliver new treatments for people suffering from dry eye."

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.